DSP-0187 by Jazz Pharmaceuticals for Narcolepsy: Likelihood of Approval
DSP-0187 by Jazz Pharmaceuticals for Narcolepsy: Likelihood of Approval
DSP-0187 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Smarter leaders trust GlobalData The gold standard of business intelligence. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. DSP-0187 overview DSP-0187 is under development for the treatment of narcolepsy and idiopathic hypersomnia. It is administered through oral route. The therapeutic candidates act by targeting orexin 2 receptor. Jazz Pharmaceuticals overview Jazz Pharmaceuticals is a specialty biopharmaceutical company which identifies, develops, and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Erwinaze (asparaginase erwinia chrysanthemi), Defitelio (defibrotide sodium), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland. For a complete picture of DSP-0187’s drug-specific PTSR and LoA scores, This content was updated on 11 March 2023 Give your business an edge with our leading industry insights. From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s . Smarter leaders trust GlobalData The gold standard of business intelligence.
Publish Date : 2023-11-19 01:19:36
Image and News Source : pharmaceutical_technology